Takeda makes US R&D appointment
This article was originally published in Scrip
Dr Azmi Nabulsi has been appointed president of the Takeda Global Research & Development Center in the US. He succeeds Dr Nancy Joseph-Ridge, who has been named general manager of the Japanese firm's US pharmaceutical development division. This operates under Takeda Pharmaceuticals International, a new wholly owned US entity formed in a recent restructuring of corporate R&D activities (scripnews.com, March 31st, 2009). Dr Nabulsi joined Takeda in 2004 and was most recently general manager of the strategic development department at its Osaka headquarters.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.